FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304081> ?p ?o ?g. }

• W4367304081 abstract "<h3>Objective:</h3> To describe the design of a clinical trial that will evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenously administered TAK-341 in participants with multiple system atrophy (MSA). <h3>Background:</h3> MSA is a rapidly progressing and fatal neurological disorder, with no treatments that can slow its progression. TAK-341 (MEDI1341) is a monoclonal antibody that binds to the C-terminal region of human alpha-synuclein. In a mouse model, TAK-341 attenuated cell-to-cell spreading of alpha-synuclein pathology in the brain. Single ascending dose (NCT03272165) and multiple ascending dose (NCT04449484) studies in healthy participants and participants with Parkinson disease, respectively, have recently completed and support continued development of TAK-341. <h3>Design/Methods:</h3> This randomized, double-blind, placebo-controlled, Ph2 study (NCT05526391) will enroll approximately 138 participants globally who are ≥40 years of age, with probable or possible MSA according to modified Gilman 2008 criteria. Participants’ onset of MSA symptoms must have occurred ≤4 years before screening as demonstrated by MSA symptoms measured with the Unified MSA Rating Scale (UMSARS). Participants will receive 13 intravenous infusions of either TAK-341 or placebo, approximately every 4 weeks. The study comprises a ≤42-day screening period, a 52-week double-blind treatment period, and a follow-up safety visit. The study’s primary objective is to evaluate the efficacy of TAK-341 versus placebo, as measured by the change from baseline after 52 weeks on a modified UMSARS Part I. Secondary objectives are to evaluate the efficacy of TAK-341 versus placebo, as measured by change from baseline after 52 weeks on the following: UMSARS Part I, Part II, and total scores, an 11-item selection of UMSARS Part I and II items, CGI-S, SCOPA-AUT, and overall survival. Secondary objectives also include evaluation of pharmacokinetic parameters. Safety endpoints will also be evaluated. <h3>Results:</h3> Recruiting <h3>Conclusions:</h3> Trial results will yield insight into the role of alpha-synuclein in MSA disease progression, and further inform TAK-341’s risk-benefit profile. <b>Disclosure:</b> Jaya Padmanabhan has received personal compensation for serving as an employee of Takeda Pharmaceuticals. Jaya Padmanabhan has stock in Takeda Pharmaceuticals. Dr. Ratti has received personal compensation for serving as an employee of Takeda. Dr. Ratti has received personal compensation for serving as an employee of Biogen. Dr. Ratti has stock in Takeda. Dr. Ratti has stock in Biogen. Dr. Khudyakov has nothing to disclose. Wei Yin has received personal compensation for serving as an employee of Takeda. Wei Yin has stock in Takeda. Mr. Zicha has stock in Takeda Pharmaceutical Company Ltd. Dr. Golonzhka has nothing to disclose. Tairmae Kangarloo has nothing to disclose. Brian Harel has received personal compensation for serving as an employee of Takeda. An immediate family member of Brian Harel has received personal compensation for serving as an employee of Astra Zeneca. Brian Harel has stock in Takeda, Merck, Day One Biopharmaceuticals. An immediate family member of Brian Harel has stock in Eli Lilly, Pfizer, Astra Zeneca. Mrs. Goodman has nothing to disclose. Mrs. Magueur has received personal compensation for serving as an employee of Takeda . Mrs. Magueur has stock in Takeda Pharmaceuticals. Dr. Shering has received personal compensation for serving as an employee of AstraZeneca. An immediate family member of Dr. Shering has received personal compensation for serving as an employee of eResearch Technology Inc. Dr. Shering has stock in AstraZeneca. Dr. Shering has received intellectual property interests from a discovery or technology relating to health care. Dr. Ostenfeld has received personal compensation for serving as an employee of AstraZeneca. Dr. Ostenfeld has stock in AstraZeneca. Dr. Ostenfeld has received intellectual property interests from a discovery or technology relating to health care. Dr. Laurenza has received personal compensation for serving as an employee of Takeda. Dr. Laurenza has stock in Takeda. Arthur Simen has received personal compensation for serving as an employee of Takeda." @default.
• W4367304081 created "2023-04-29" @default.
• W4367304081 creator A5025233834 @default.
• W4367304081 creator A5026040566 @default.
• W4367304081 creator A5027293712 @default.
• W4367304081 creator A5030949544 @default.
• W4367304081 creator A5031039877 @default.
• W4367304081 creator A5034856580 @default.
• W4367304081 creator A5045681106 @default.
• W4367304081 creator A5048708699 @default.
• W4367304081 creator A5057426739 @default.
• W4367304081 creator A5058205777 @default.
• W4367304081 creator A5062252709 @default.
• W4367304081 creator A5074921549 @default.
• W4367304081 creator A5076736990 @default.
• W4367304081 creator A5086604821 @default.
• W4367304081 date "2023-04-25" @default.
• W4367304081 modified "2023-10-14" @default.
• W4367304081 title "Study Design of TAK-341-2001: A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-341 in Subjects With Multiple System Atrophy (P9-9.003)" @default.
• W4367304081 doi "https://doi.org/10.1212/wnl.0000000000201834" @default.
• W4367304081 hasPublicationYear "2023" @default.
• W4367304081 type Work @default.
• W4367304081 citedByCount "0" @default.
• W4367304081 crossrefType "proceedings-article" @default.
• W4367304081 hasAuthorship W4367304081A5025233834 @default.
• W4367304081 hasAuthorship W4367304081A5026040566 @default.
• W4367304081 hasAuthorship W4367304081A5027293712 @default.
• W4367304081 hasAuthorship W4367304081A5030949544 @default.
• W4367304081 hasAuthorship W4367304081A5031039877 @default.
• W4367304081 hasAuthorship W4367304081A5034856580 @default.
• W4367304081 hasAuthorship W4367304081A5045681106 @default.
• W4367304081 hasAuthorship W4367304081A5048708699 @default.
• W4367304081 hasAuthorship W4367304081A5057426739 @default.
• W4367304081 hasAuthorship W4367304081A5058205777 @default.
• W4367304081 hasAuthorship W4367304081A5062252709 @default.
• W4367304081 hasAuthorship W4367304081A5074921549 @default.
• W4367304081 hasAuthorship W4367304081A5076736990 @default.
• W4367304081 hasAuthorship W4367304081A5086604821 @default.
• W4367304081 hasConcept C111113717 @default.
• W4367304081 hasConcept C112705442 @default.
• W4367304081 hasConcept C126322002 @default.
• W4367304081 hasConcept C142724271 @default.
• W4367304081 hasConcept C168563851 @default.
• W4367304081 hasConcept C187212893 @default.
• W4367304081 hasConcept C197934379 @default.
• W4367304081 hasConcept C202061045 @default.
• W4367304081 hasConcept C204787440 @default.
• W4367304081 hasConcept C27081682 @default.
• W4367304081 hasConcept C2778375690 @default.
• W4367304081 hasConcept C2781172350 @default.
• W4367304081 hasConcept C2991744798 @default.
• W4367304081 hasConcept C535046627 @default.
• W4367304081 hasConcept C71924100 @default.
• W4367304081 hasConceptScore W4367304081C111113717 @default.
• W4367304081 hasConceptScore W4367304081C112705442 @default.
• W4367304081 hasConceptScore W4367304081C126322002 @default.
• W4367304081 hasConceptScore W4367304081C142724271 @default.
• W4367304081 hasConceptScore W4367304081C168563851 @default.
• W4367304081 hasConceptScore W4367304081C187212893 @default.
• W4367304081 hasConceptScore W4367304081C197934379 @default.
• W4367304081 hasConceptScore W4367304081C202061045 @default.
• W4367304081 hasConceptScore W4367304081C204787440 @default.
• W4367304081 hasConceptScore W4367304081C27081682 @default.
• W4367304081 hasConceptScore W4367304081C2778375690 @default.
• W4367304081 hasConceptScore W4367304081C2781172350 @default.
• W4367304081 hasConceptScore W4367304081C2991744798 @default.
• W4367304081 hasConceptScore W4367304081C535046627 @default.
• W4367304081 hasConceptScore W4367304081C71924100 @default.
• W4367304081 hasLocation W43673040811 @default.
• W4367304081 hasOpenAccess W4367304081 @default.
• W4367304081 hasPrimaryLocation W43673040811 @default.
• W4367304081 hasRelatedWork W1490315633 @default.
• W4367304081 hasRelatedWork W1541406077 @default.
• W4367304081 hasRelatedWork W2149042564 @default.
• W4367304081 hasRelatedWork W2179347738 @default.
• W4367304081 hasRelatedWork W2194222775 @default.
• W4367304081 hasRelatedWork W2328878243 @default.
• W4367304081 hasRelatedWork W2366120589 @default.
• W4367304081 hasRelatedWork W2919885841 @default.
• W4367304081 hasRelatedWork W3159937175 @default.
• W4367304081 hasRelatedWork W3207313530 @default.
• W4367304081 isParatext "false" @default.
• W4367304081 isRetracted "false" @default.
• W4367304081 workType "article" @default.